Fig. 2From: EGFR T790M detection and osimertinib treatment response evaluation by liquid biopsy in lung adenocarcinoma patients with acquired resistance to first generation EGFR tyrosine kinase inhibitorsDistribution of T790 M positive and negative cases in stage IIIB-IVB NSCLC patients with acquired resistance to first generation EGFR TKIs. a.ctDNA T790 M mutation detected by ddPCR; b.ctDNA T790 M mutation detected by CobasBack to article page